Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P-1037 + hypertonic saline
- Development stage
- Unknown
- Lead developer
- Parion Sciences
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
**P-1037 + hypertonic saline** is a combination drug therapy investigated for cystic fibrosis (CF), consisting of P-1037 (also known as VX-371), an inhaled epithelial sodium channel (ENaC) inhibitor, and hypertonic saline administered via inhalation. P-1037 works by blocking the ENaC on airway cells, reducing sodium absorption, thereby prolonging airway hydration and improving mucus clearance. Hypertonic saline increases the salt concentration in airway secretions, drawing water into the mucus via osmosis and reducing viscosity for easier clearance. Together, this combination targets the mucociliary dysfunction in CF, aiming to thin mucus and enhance pulmonary function. The developer for P-1037 is Vertex Pharmaceuticals, in collaboration with Parion Sciences[3].
- Brand names
- VX-371VX371VX 371
- Other names
- VX-371VX371VX 371P-1037/hypertonic saline
02
Targets
ENaC
Beyond the preview
Go deeper on P-1037 + hypertonic saline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P-1037 + hypertonic saline.